UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (date of earliest event reported): December 21, 2007
COUGAR BIOTECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
000-51473 20-2903204
(Commission File Number) (IRS Employer Identification No.)
10990 Wilshire Blvd, Suite 1200
Los Angeles, CA 90024
(Address of principal executive offices) (Zip Code)
(310) 943-8040 (Registrant's telephone
number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[_] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
(a) Closing of Private Placement
On December 14, 2007, Cougar Biotechnology, Inc. (the "Company") entered
into a securities purchase agreement (the "Purchase Agreement") with various
institutional investors relating to the sale in a private placement of an
aggregate of 3,000,000 shares of its common stock at a price of $29.00 per
share, the terms of which were disclosed by the Company in a Current Report on
Form 8-K filed with the Securities and Exchange Commission on December 17, 2007.
On December 21, 2007, the Company completed the sale of the shares as
contemplated under the Purchase Agreement.
(b) Initiation of Phase I Trial for CB3304
On December 21, 2007, the Company issued a press release relating to the
enrollment of the first patient in a Phase I trial of the Company's drug
candidate CB3304 (noscapine). A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release dated December 21, 2007.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
COUGAR BIOTECHNOLOGY, INC.
Date: December 21, 2007 By: /s/ Charles R. Eyler
--------------------------------------
Charles R. Eyler
Treasurer and Vice President, Finance
2
INDEX TO EXHIBITS FILED WITH THIS REPORT
Ex. No. Description
- ------- -----------
99.1 Press Release dated December 21, 2007.